BRÈVE

sur Relief Therapeutics Holding SA (ETR:RLF)

MindMaze Therapeutics Secures CHF 4 Million Financing for Growth

MindMaze Therapeutics, based in Geneva, Switzerland, has announced new financing agreements totaling CHF 4 million. This funding, sourced from long-term strategic investors, will fuel the commercial expansion of its precision neurotherapeutics platform. The company has clinically validated solutions and a commercial framework in place, aiming to broaden its customer base and boost revenue growth. The introduction of MindMotion Lite, a tablet-based solution for home use, is central to this strategy.

The financing package includes CHF 3 million earmarked for the end of 2026, with an additional CHF 1 million option available until February 2027. This deal consists mainly of shares and convertible notes priced at CHF 0.12 per share. MindMaze has also concluded a CHF 4 million unfunded commitment from a prior financing arrangement in May 2026.

R. H.

Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de Relief Therapeutics Holding SA